Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.
Herling CD, et al. Among authors: abrams zb.
Lancet Oncol. 2019 Nov;20(11):1576-1586. doi: 10.1016/S1470-2045(19)30503-0. Epub 2019 Sep 30.
Lancet Oncol. 2019.
PMID: 31582354
Free PMC article.
Clinical Trial.